- Home
- GPCR vs MYGN Comparison
GPCR vs MYGN Comparison
Compare GPCR & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPCR
- MYGN
- Stock Information
- Founded
- GPCR 2016
- MYGN 1991
- Country
- GPCR United States
- MYGN United States
- Employees
- GPCR N/A
- MYGN N/A
- Industry
- GPCR
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GPCR
- MYGN Health Care
- Exchange
- GPCR Nasdaq
- MYGN Nasdaq
- Market Cap
- GPCR 1.8B
- MYGN 2.0B
- IPO Year
- GPCR 2023
- MYGN 1995
- Fundamental
- Price
- GPCR $34.17
- MYGN $15.25
- Analyst Decision
- GPCR Buy
- MYGN Buy
- Analyst Count
- GPCR 5
- MYGN 12
- Target Price
- GPCR $86.80
- MYGN $27.64
- AVG Volume (30 Days)
- GPCR 677.5K
- MYGN 990.7K
- Earning Date
- GPCR 11-13-2024
- MYGN 11-07-2024
- Dividend Yield
- GPCR N/A
- MYGN N/A
- EPS Growth
- GPCR N/A
- MYGN N/A
- EPS
- GPCR N/A
- MYGN N/A
- Revenue
- GPCR N/A
- MYGN $823,600,000.00
- Revenue This Year
- GPCR N/A
- MYGN $13.85
- Revenue Next Year
- GPCR N/A
- MYGN $7.73
- P/E Ratio
- GPCR N/A
- MYGN N/A
- Revenue Growth
- GPCR N/A
- MYGN 12.15
- 52 Week Low
- GPCR $26.61
- MYGN $15.18
- 52 Week High
- GPCR $66.38
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- GPCR 35.81
- MYGN 16.18
- Support Level
- GPCR $33.85
- MYGN $16.86
- Resistance Level
- GPCR $38.48
- MYGN $19.60
- Average True Range (ATR)
- GPCR 2.62
- MYGN 1.17
- MACD
- GPCR -0.36
- MYGN -0.25
- Stochastic Oscillator
- GPCR 3.67
- MYGN 0.90
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.